Organon & Co
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $19.29
- Today's High:
- $19.8499
- Open Price:
- $19.63
- 52W Low:
- $18.6389
- 52W High:
- $31.2766
- Prev. Close:
- $19.67
- Volume:
- 3280794
Company Statistics
- Market Cap.:
- $5.66 billion
- Book Value:
- -2.172
- Revenue TTM:
- $6.17 billion
- Operating Margin TTM:
- 24.19%
- Gross Profit TTM:
- $3.89 billion
- Profit Margin:
- 12.22%
- Return on Assets TTM:
- 8.64%
- Return on Equity TTM:
- 0%
Company Profile
Organon & Co had its IPO on 2021-06-02 under the ticker symbol OGN.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Organon & Co has a staff strength of 10,000 employees.
Stock update
Shares of Organon & Co opened at $19.63 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $19.29 - $19.85, and closed at $19.44.
This is a -1.17% slip from the previous day's closing price.
A total volume of 3,280,794 shares were traded at the close of the day’s session.
In the last one week, shares of Organon & Co have slipped by -12.2%.
Organon & Co's Key Ratios
Organon & Co has a market cap of $5.66 billion, indicating a price to book ratio of 1.8433 and a price to sales ratio of 1.1433.
In the last 12-months Organon & Co’s revenue was $6.17 billion with a gross profit of $3.89 billion and an EBITDA of $1.72 billion. The EBITDA ratio measures Organon & Co's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Organon & Co’s operating margin was 24.19% while its return on assets stood at 8.64% with a return of equity of 0%.
In Q2, Organon & Co’s quarterly earnings growth was a positive 3% while revenue growth was a positive 1.5%.
Organon & Co’s PE and PEG Ratio
- Forward PE
- 5.0302
- Trailing PE
- 7.5051
- PEG
Its diluted EPS in the last 12-months stands at $2.95 per share while it has a forward price to earnings multiple of 5.0302 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Organon & Co’s profitability.
Organon & Co stock is trading at a EV to sales ratio of 2.3968 and a EV to EBITDA ratio of 8.0645. Its price to sales ratio in the trailing 12-months stood at 1.1433.
Organon & Co stock pays annual dividends of $1.12 per share, indicating a yield of 5.1% and a payout ratio of 24.78%.
Balance sheet and cash flow metrics
- Total Assets
- $10.98 billion
- Total Liabilities
- $2.39 billion
- Operating Cash Flow
- $-70000000.00
- Capital Expenditure
- $71 million
- Dividend Payout Ratio
- 24.78%
Organon & Co ended 2024 with $10.98 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $10.98 billion while shareholder equity stood at $-555000000.00.
Organon & Co ended 2024 with $32.00 million in deferred long-term liabilities, $2.39 billion in other current liabilities, 3000000.00 in common stock, $-25000000.00 in retained earnings and $4.60 billion in goodwill. Its cash balance stood at $326.00 million and cash and short-term investments were $326.00 million. The company’s total short-term debt was $8,000,000 while long-term debt stood at $8.72 billion.
Organon & Co’s total current assets stands at $3.96 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.67 billion compared to accounts payable of $1.12 billion and inventory worth $1.20 billion.
In 2024, Organon & Co's operating cash flow was $-70000000.00 while its capital expenditure stood at $71 million.
Comparatively, Organon & Co paid $0.25 in dividends in 2024.
Other key metrics
- Current Trading Price
- $19.44
- 52-Week High
- $31.2766
- 52-Week Low
- $18.6389
- Analyst Target Price
- $30.33
Organon & Co stock is currently trading at $19.44 per share. It touched a 52-week high of $31.2766 and a 52-week low of $31.2766. Analysts tracking the stock have a 12-month average target price of $30.33.
Its 50-day moving average was $21.32 and 200-day moving average was $23.38 The short ratio stood at 2.95 indicating a short percent outstanding of 0%.
Around 10.3% of the company’s stock are held by insiders while 7976.5% are held by institutions.
Frequently Asked Questions About Organon & Co
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.